Zambon
Zambon is an Italian pharmaceutical and fine-chemicals group founded in 1906.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Zambon is an Italian pharmaceutical and fine-chemicals company whose roots date to a medical-products warehouse established in Vicenza in 1906 by pharmacist Gaetano Zambon and his business partner Silvio Farina. What began as a distributor of basic medicinal substances and pharmacy commodities developed into an integrated healthcare group with activities spanning pharmaceutical development, manufacturing, fine chemicals, commercial operations and research investment. The company initially supplied pharmacies with materials including bismuth, iodine and bicarbonate, as well as products such as liquorice, spices and talcum powder. During the 1920s it moved beyond distribution by establishing laboratories for specialty products and galenic formulations under the ZeF name. The business added manufacturing capacity during the interwar period, including a synthetic-products department that helped connect raw-material processing with finished pharmaceutical production. The Second World War severely damaged the company’s plant, but Zambon rebuilt after the conflict and resumed expansion. During the post-war transition, management passed to the younger generation of the family. Alberto Zambon subsequently guided the company’s development, strengthened international relationships and promoted the creation of proprietary medicines rather than relying solely on licensing arrangements. In 1961, the corporate headquarters and research laboratories moved to Bresso near Milan, while production remained associated with Vicenza. International growth became a central feature of the group. Zambon established or expanded operations in Brazil, Spain, Switzerland, France, Colombia, the United Kingdom, the Netherlands, Belgium, China, India and Indonesia, among other markets. Its Spanish business was established in Barcelona in 1960 to serve the Iberian Peninsula; Spain is associated particularly with the Ultra Levura probiotic product. The group also developed a substantial fine-chemicals platform, including manufacturing capacity in Italy and China. Zambon’s pharmaceutical portfolio has included respiratory medicines, mucolytic products, treatments for central nervous system disorders and products for other specialist therapeutic areas. Fluimucil became one of its important international respiratory brands. In 2013 the group acquired Profile Pharma in the United Kingdom, a company focused on cystic-fibrosis products, reinforcing Zambon’s interest in respiratory disease and rare conditions. Around the same period, Zambon entered the central nervous system field through work involving safinamide, a medicine for Parkinson’s disease. The modern group is organized around Zambon Company S.p.A. as an industrial holding structure, with Zambon S.p.A. focused on pharmaceuticals, Zach System focused on fine chemicals and Z-Cube focused on research and venture activities. The company has been described as operating across three continents and employing approximately 2,600 people in 15 countries. It remains a family-controlled Italian healthcare group, with Elena Zambon identified as its current leader and a member of the founder’s family.
History
Zambon’s history began in Vicenza, Italy, where pharmacist Gaetano Zambon and Silvio Farina acquired a medical-products warehouse in August 1906. The business was formally established as the Zambon Medical Products Warehouse on 11 November 1906. Its early activity was primarily distribution: it supplied pharmacies with basic pharmaceutical substances such as bismuth, iodine and bicarbonate, while also handling commodities including liquorice, spices and talcum powder. In 1908, the partners created Gaetano Zambon & Co., adding Teodorico Viero to the ownership structure. Regional growth soon required larger premises. Although the First World War slowed commercial activity, the company continued operating and served the Military Medical Corps. In the years after the war, the business developed small-scale manufacturing of pharmacy products, including quinine-based preparations, iron and quinine formulations, rhubarb products and insecticide. In 1920, Zambon and its partners created a laboratory for specialty products and galenic formulations under the ZeF name, derived from Zambon and Farina. The company strengthened its industrial base during the 1930s. It acquired an older fertilizer plant in 1930 and established a synthetic-products department in 1933. These steps allowed Zambon to integrate more of the route from chemical inputs to finished pharmaceutical products. In 1938, after Teodorico Viero’s departure, the company was reorganized as Zambon & C. Società Anonima per Azioni. Its workforce expanded substantially during the following decade. The Second World War brought a major setback. The factory was heavily damaged by bombing on 14 May 1944. Reconstruction was completed after the war, and a new Zambon plant opened in September 1946. The company also began selling its pharmaceutical products abroad. During the post-war generational transition, the original partners’ interests were gradually separated. The Farina branch left in 1951 and the Ferraris followed in 1957. Alberto Zambon then assumed management, while Gaetano Zambon died in 1959. The company adopted the name Zambon S.p.A. Alberto Zambon pursued international development and built relationships with American companies and other large pharmaceutical businesses, particularly in research. His strategy emphasized the development of Zambon’s own medicines rather than depending exclusively on licensed products. The group opened a Brazilian production operation in 1956 and established Zambon S.A. in Barcelona in 1960 to cover the Iberian Peninsula. In 1961, headquarters and research laboratories moved to Bresso near Milan, although the Vicenza area remained important for production. The 1960s and 1970s brought a wider international network. Inpharzam was established in Switzerland in 1963 to coordinate international activities, while Zambon France was created to support sales and exports to Africa and Australia. Fluimucil entered the market in 1965. The company also developed a relationship with Japan’s Eisai and built a new chemical-ingredients plant at Almisano di Lonigo in 1970. Zambon Colombia was established in 1975. Expansion continued through acquisitions, subsidiaries and joint ventures. Zambon acquired Simes in 1983 and moved production to a new Vicenza facility in 1984. Dutch operations were established during the same period, followed by United Kingdom and United States operations in 1989. The group formed a Belgian Inpharzam operation in 1995 and created a Chinese chemical joint venture at Shantou in 1996; the Shantou plant opened in 1997. A second Chinese plant opened in Hainan in 2000, separating chemical and pharmaceutical production between the two locations. Zambon India was established in 2002 and Zambon Indonesia in 2004. In the twenty-first century, Zambon placed particular emphasis on respiratory medicine, including chronic obstructive pulmonary disease, cystic fibrosis and other serious or rare conditions. Its 2013 acquisition of Profile Pharma in the United Kingdom added expertise and products in cystic fibrosis. The group also expanded into central nervous system therapy through safinamide, reflecting a broader specialist-pharmaceutical strategy. Today, the group’s organization includes Zambon Company S.p.A. as an industrial holding company, Zambon S.p.A. for pharmaceuticals, Zach System for fine chemicals and Z-Cube for research and venture activity. The company operates across Europe, South America and Asia and has been described as having approximately 2,600 employees in 15 countries. It continues to operate as a family-controlled Italian healthcare enterprise under the leadership of Elena Zambon.
- 2013
Profile Pharma acquired
[1]Zambon acquired Profile Pharma in the United Kingdom to strengthen its cystic-fibrosis and specialist-respiratory portfolio.
- 2000
Second Chinese plant opened
[1]A second plant opened in Hainan, with chemical and pharmaceutical production divided between the Chinese sites.
- 1996
Chinese chemical joint venture formed
[1]Shantou Shanning Zambon Chemicals was established as an equity joint venture.
- 1983
Simes acquired
[1]Zambon acquired Emilio Ghirardi’s Simes business, broadening its production and pharmaceutical activities.
- 1970
Fine-chemicals capacity added in Italy
[1]A new chemical-ingredients plant was built at Almisano di Lonigo.
- 1965
Fluimucil launched
[1]Zambon introduced Fluimucil, a respiratory product that became an important brand in its portfolio.
- 1961
Headquarters and research moved to Bresso
[1]The group transferred its principal headquarters and research laboratories to Bresso near Milan.
- 1960
Spanish subsidiary established
[1]Zambon established a Barcelona-based company serving Spain and the wider Iberian Peninsula.
- 1956
Brazilian production operation established
[1]Zambon opened its first production facility in Brazil.
- 1946
Post-war plant reopened
[1]A new Zambon plant opened in September 1946 as the company rebuilt its industrial operations.
Products and positioning
A privately held, research-oriented Italian healthcare group combining branded pharmaceuticals, specialist respiratory and central-nervous-system therapies, and fine-chemicals manufacturing.
Respiratory medicine · 1965
Fluimucil
Fluimucil is a Zambon respiratory brand introduced in 1965. It is associated with mucolytic treatment and has been marketed internationally as part of the company’s long-standing focus on respiratory care.
Probiotic treatment
Ultra Levura
Ultra Levura is a probiotic treatment identified as a leading Zambon brand in Spain. It represents the company’s consumer-facing and pharmacy-oriented healthcare activity in the Spanish market.
Central nervous system medicine
Safinamide
Safinamide is a central nervous system medicine associated with Zambon’s entry into Parkinson’s disease treatment. Its development marked a strategic expansion beyond the company’s traditional respiratory focus.
Brand decisions
2013
Acquisition of Profile PharmaM&ABackground
Zambon was seeking to deepen its position in respiratory diseases, including cystic fibrosis and rare conditions.
Action taken
The group acquired Profile Pharma in the United Kingdom, adding specialist cystic-fibrosis capabilities.
Aftermath
The transaction reinforced respiratory medicine as a strategic area for Zambon and complemented its existing pharmaceutical portfolio.
2013
Expansion into central nervous system therapiesStrategyBackground
Zambon had historically been strongly associated with respiratory and pharmaceutical products and sought to broaden its specialist therapeutic presence.
Action taken
The company entered the central nervous system field through its involvement with safinamide for Parkinson’s disease.
Aftermath
The move diversified Zambon’s research and commercial focus into neurology.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/zambon · Editorial policy · How profiles are compiled